GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoZenge AB (FRA:8LY) » Definitions » Valuation Rank

OncoZenge AB (FRA:8LY) Valuation Rank


View and export this data going back to 2021. Start your Free Trial

What is OncoZenge AB Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.


OncoZenge AB Valuation Rank Related Terms

Thank you for viewing the detailed overview of OncoZenge AB's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoZenge AB Business Description

Traded in Other Exchanges
Address
Gustavslundsvagen 34, Bromma, SWE, 167 51
OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.